A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
Status:
Completed
Trial end date:
2021-01-11
Target enrollment:
Participant gender:
Summary
A study to evaluate the safety and tolerability of DKN-01 in combination with weekly
paclitaxel or pembrolizumab in participants with relapsed or refractory Esophagogastric
Malignancies